dr. kolberg on cost-effectiveness of pertuzumab in her2-positive breast cancer
Published 8 years ago • 270 plays • Length 1:51Download video MP4
Download video MP3
Similar videos
-
1:55
dr. kolberg on collecting real-world biosimilar trastuzumab data in breast cancer
-
1:27
dr. hans-christian kolberg on safer chemotherapy for patients with her2-positive early breast cancer
-
2:27
dr. kolberg on the safety profile of trastuzumab biosimilars in breast cancer
-
0:47
dr. yee on neoadjuvant pertuzumab in her2-positive breast cancer
-
1:53
dr. pegram on pertuzumab combination for her2-positive breast cancer
-
1:56
dr. kolberg on the lilac study in breast cancer
-
3:14
abp 980, a trastuzumab biosimilar in combination with pertuzumab
-
1:05
dr. pegram on pertuzumab plus trastuzumab and chemotherapy in breast cancer
-
6:00
frontline pertuzumab for metastatic breast cancer
-
4:32
cleopatra trial: pertuzumab regimen for frontline her2-positive metastatic breast cancer
-
2:27
dr. yardley on the aphinity trial for her2-positive breast cancer
-
1:52
dr. geyer discusses pertuzumab in her2 breast cancer
-
1:24
dr. tolaney discusses pertuzumab in her2 breast cancer
-
2:31
dr. peter beitsch on pertuzumab in luminal subtype breast cancer
-
1:45
dr. verma on advancements in treatment of her2-positive breast cancer
-
1:30
dr. hudis on neoadjuvant treatment of her2-positive breast cancer
-
5:11
the importance of central pathology pcr review in an international multicenter neoadjuvant study...
-
1:49
dr. esteva on trastuzumab biosimilar in patients with her2 breast cancer
-
3:52
case study: her2-positive oligometastatic breast cancer